nanoComposix is now a Fortis Life Sciences Company. Learn more + Email Newsletter Signup

The Upcoming Revolution in Lateral Flow Diagnostics

October 14, 2016

Learn how ultrasensitive nanoparticle probes, covalent binding chemistry, and quantitative smartphone-based readers are inspiring an explosion in the use and potential of lateral flow diagnostics. These advances enable the detection of ultra-low concentration biomarkers and are opening the door to the diagnosis of diseases and early-stage conditions previously undetectable by lateral flow.